Jade Parker on Muck Rack

Jade Parker

London
As seen in: Oncology Central, Bandcamp Daily, Lawfare, Lexology, Future Medicine, Biotechniques: the International Journal of Life Science Methods, DIY Active, Chattr, Neuro Central
Tea connoisseur. Mama. 90's specialist. Love all things #SciComms Senior Editor of @oncologycentral
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jade

Contact Jade, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

First patient receives TCR-T cell therapy targeting mutant KRAS pancreatic cancer

|
By Jade Parker
| Oncology Central Verified
Discover the latest breakthroughs in cancer cell therapies in this edition of RegMedNet’s Cell Therapy Weekly, including news that the first patient has been dosed with a novel T cell receptor-modified T cell therapy targeting KRAS G12V mutations in an aggressive form of pancreatic cancer and key updates in the progress made in developing programmable T-cell and macrophage therapies for solid tumors. Find out more
Open in Who Shared Issue with article?

Men Are Sharing Things They Find Unattractive In Women and It’s Starting an Important Conversation Online

|
By Jade Parker
| buzztimes24.com
This article was originally published on Constative.com For centuries women have been wondering what goes on in the minds of men. Millions of books, movies, and research were conducted to help them understand exactly how men operate and their likes and dislikes. However, despite all this monumental effort, there still seem to be a lot of unanswered questions.
Open in Who Shared Issue with article?

ASCO 2026: Multi-selective RAS(ON) inhibitor yields unprecedented survival gains for metastatic pancreatic cancer

|
By Jade Parker
| Oncology Central Verified
Original story from the ASCO Annual Meeting Results from the first phase 3 trial of a RAS(ON) multi-selective inhibitor show that daraxonrasib is effective for RAS-mutant and RAS-wild-type metastatic pancreatic ductal adenocarcinoma (mPDAC). In people who have received treatment, daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy.
Open in Who Shared Issue with article?
See all 545 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified